Abstract
Transitioning from administration of monthly palivizumab to a single dose at discharge was associated with substantial pharmacy cost savings. With the concurrent adoption of private hospital rooms and visitor restriction policies, hospital-wide and neonatal intensive care unit healthcare-associated respiratory syncytial virus infections decreased following these changes. Infect Control Hosp Epidemiol 2018;39:485-487.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Antiviral Agents / administration & dosage
-
Chemoprevention / economics
-
Chemoprevention / methods
-
Chemoprevention / statistics & numerical data
-
Cost Savings / methods
-
Cross Infection* / epidemiology
-
Cross Infection* / prevention & control
-
Cross Infection* / virology
-
Drug Administration Schedule
-
Female
-
Humans
-
Infant, Newborn
-
Infection Control* / methods
-
Infection Control* / organization & administration
-
Male
-
Palivizumab / administration & dosage*
-
Palivizumab / economics
-
Patient Discharge
-
Policy Making
-
Respiratory Syncytial Virus Infections* / epidemiology
-
Respiratory Syncytial Virus Infections* / prevention & control
-
Risk Factors
-
United States / epidemiology
Substances
-
Antiviral Agents
-
Palivizumab